Article Drug pipeline

From Diabetes to Breast Cancer: Promise, Uncertainty, and the Case for Prospective Trials of GLP-1 Receptor Agonists

GLP-1 receptor agonists have transformed the treatment of type 2 diabetes and obesity. Now, researchers are exploring a new question: Could these medications also play a…

By Richa Madurkar

Article Drug pipeline

Managed Care Implications of Fixed-Duration Lenalidomide Maintenance in Multiple Myeloma (MM)

Is Shorter Duration Therapy Less Effective Than Indefinite Maintenance? The phase 3 ENDURANCE (E1A11) trial provides compelling evidence regarding the duration of lenalidomide maintenance in patients…

By Melissa Pozotrigo

Article Drug pipeline

The End of “Undruggable?”: Why RASolute-302 May Mark the Beginning of the Pan-RAS Era

The phase 3 RASolute-302 trial marks a potential turning point in oncology, demonstrating that pan-RAS inhibition with daraxonrasib may significantly improve survival in metastatic pancreatic cancer.…

By Corey Wise

Article Drug pipeline

Translating ASCO 2026: What Matters Most for Managed Care

ASCO 2026, the largest oncology conference in the world, featured groundbreaking clinical trial results expected to transform standards of care (SoC) in oncology. For payors, staying…

By Richa Madurkar

Article Precision medicine

Minimal Residual Disease in Oncology

Minimal residual disease (MRD) testing has become one of the most important advances in cancer care over the past twenty years. It can find very small…

By Melissa Pozotrigo

Article Supportive care

Why Mental Health Support Is Critical to Improving Oncology Outcomes

Cancer care is often measured in clinical milestones such as diagnosis, treatment, and remission. But for many individuals, the experience extends beyond physical care. Mental health…

Article Drug pipeline

Innovations in Bladder Cancer Therapy: Implications for Managed Care

The treatment landscape for bladder cancer is rapidly evolving. Additional therapeutic options have been recently approved or are in the pipeline for patients in both non-muscle…

By Adam Leikensohn and Richa Madurkar

Article Precision medicine

The Rising Complexity of Genetic and Molecular Testing in Oncology: Three Challenges Health Plans Can’t Ignore

Genetic and molecular testing is transforming oncology care, but it is also introducing a new layer of complexity, cost, and clinical risk for health plans.

Article Supportive care

Why Supportive Care Is Now Core to Oncology Strategy

Supportive care is becoming essential to modern oncology strategy, helping address patients’ emotional, physical, financial, and treatment-related needs to improve outcomes, reduce costs, and enhance the…

Article Drug pipeline

Front-Line Covalent BTK Inhibitor + Venetoclax ± Obinutuzumab: A New Triple Threat?

Emerging front-line chronic lymphocytic leukemia (CLL) treatment options combine covalent BTK inhibitors with venetoclax and obinutuzumab, prompting new considerations around clinical benefit, risk, and cost compared…

By Richa Madurkar

Article Cost and utilization

The New Cancer Curveball: Why Rising Rates Among Working Adults Could Hit Your Wallet Too

Health insurance premiums are projected to see their largest increase in 15 years — and rising cancer rates among working-age adults are partly to blame. Here’s…

By Corey Wise

Article Supportive care

3 Ways Malnutrition in Cancer Care is Driving up Costs for Health Plans

Malnutrition in cancer care is more than a clinical issue; it’s a financial one. Here are three areas where malnutrition has the biggest financial impact on…